- Retired indicators replaced with new indicators – CHD015, CHD016, DM012, HF003, HF006, HYP008, HYP009, NDH002, STIA014, STIA015
- Existing register changes – asthma, to include patients from aged 5, COPD to address potential under/over recording
- New indicators – CD001/CD002 blood pressure control indicators, DM037 annual diabetes care processes indicator, HF009 four-pillar therapy in HF, OB004/OB005 obesity management
- Points & threshold changes are applicable throughout to some existing indicators
- Moderate & severely frail patients have been removed from the hypertension indicators HYP010/HYP011
- Gestational diabetes added to the NDH register
QOF – Obesity
- Obesity register/TPG: Patients aged 18 years or over with a body mass index (BMI) greater than or equal to 30 kg/m2 in the preceding 12 months or a BMI greater than or equal to 27.5 kg/m2 recorded in the preceding 12 months for patients with a South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family background.
- OB004 – eligible patients to be offered structured weight management support and behavioural intervention within 90 days of the BMI being recorded (moving from opportunistic case finding to proactive treatment).
- OB005 – eligible patients offered NICE approved medicines management (in a primary care setting) –
- Tirzepatide (Mounjaro) to manage obesity alongside a reduced calorie diet and increased physical activity in adults, only if they have:
- BMI 35-39.9 (was previously ≥40;);and
- ≥4 ‘qualifying’ comorbidities – hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, type 2 diabetes mellitus
Interim commissioning guidance for tirzepatide (Mounjaro®) for the management of obesity –
https://www.england.nhs.uk/wp-content/uploads/2025/03/PRN01879-interim-commissioning-guidance-implementation-of-the-nice-technology-appraisal-ta1026-and-the-NICE-fu.pdf (may be subject to local commissioning arrangements so please check with your ICB)
